These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 15177483)

  • 1. SAR of benzoylpyridines and benzophenones as p38alpha MAP kinase inhibitors with oral activity.
    Revesz L; Blum E; Di Padova FE; Buhl T; Feifel R; Gram H; Hiestand P; Manning U; Rucklin G
    Bioorg Med Chem Lett; 2004 Jul; 14(13):3601-5. PubMed ID: 15177483
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel p38 inhibitors with potent oral efficacy in several models of rheumatoid arthritis.
    Revesz L; Blum E; Di Padova FE; Buhl T; Feifel R; Gram H; Hiestand P; Manning U; Rucklin G
    Bioorg Med Chem Lett; 2004 Jul; 14(13):3595-9. PubMed ID: 15177482
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pyrazoloheteroaryls: novel p38alpha MAP kinase inhibiting scaffolds with oral activity.
    Revesz L; Blum E; Di Padova FE; Buhl T; Feifel R; Gram H; Hiestand P; Manning U; Neumann U; Rucklin G
    Bioorg Med Chem Lett; 2006 Jan; 16(2):262-6. PubMed ID: 16249085
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The identification of pyrazolo[1,5-a]pyridines as potent p38 kinase inhibitors.
    Cheung M; Harris PA; Badiang JG; Peckham GE; Chamberlain SD; Alberti MJ; Jung DK; Harris SS; Bramson NH; Epperly AH; Stimpson SA; Peel MR
    Bioorg Med Chem Lett; 2008 Oct; 18(20):5428-30. PubMed ID: 18818075
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biphenyl amide p38 kinase inhibitors 2: Optimisation and SAR.
    Angell RM; Angell TD; Bamborough P; Brown D; Brown M; Buckton JB; Cockerill SG; Edwards CD; Jones KL; Longstaff T; Smee PA; Smith KJ; Somers DO; Walker AL; Willson M
    Bioorg Med Chem Lett; 2008 Jan; 18(1):324-8. PubMed ID: 17981461
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Design, synthesis, and structure-activity relationships of aminopyridine N-oxides, a novel scaffold for the potent and selective inhibition of p38 mitogen activated protein kinase.
    Lumeras W; Caturla F; Vidal L; Esteve C; Balagué C; Orellana A; Domínguez M; Roca R; Huerta JM; Godessart N; Vidal B
    J Med Chem; 2009 Sep; 52(17):5531-45. PubMed ID: 19678708
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synthesis and biological evaluation of trisubstituted imidazole derivatives as inhibitors of p38alpha mitogen-activated protein kinase.
    Kim DK; Lim JH; Lee JA; Dewang PM
    Bioorg Med Chem Lett; 2008 Jul; 18(14):4006-10. PubMed ID: 18571921
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Design and synthesis of potent pyridazine inhibitors of p38 MAP kinase.
    Tamayo N; Liao L; Goldberg M; Powers D; Tudor YY; Yu V; Wong LM; Henkle B; Middleton S; Syed R; Harvey T; Jang G; Hungate R; Dominguez C
    Bioorg Med Chem Lett; 2005 May; 15(9):2409-13. PubMed ID: 15837335
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synthesis and structure-activity relationship of aminobenzophenones. A novel class of p38 MAP kinase inhibitors with high antiinflammatory activity.
    Ottosen ER; Sørensen MD; Björkling F; Skak-Nielsen T; Fjording MS; Aaes H; Binderup L
    J Med Chem; 2003 Dec; 46(26):5651-62. PubMed ID: 14667219
    [TBL] [Abstract][Full Text] [Related]  

  • 10. p38 MAP kinase inhibitors: metabolically stabilized piperidine-substituted quinolinones and naphthyridinones.
    Bao J; Hunt JA; Miao S; Rupprecht KM; Stelmach JE; Liu L; Ruzek RD; Sinclair PJ; Pivnichny JV; Hop CE; Kumar S; Zaller DM; Shoop WL; O'neill EA; O'keefe SJ; Thompson CM; Cubbon RM; Wang R; Zhang WX; Thompson JE; Doherty JB
    Bioorg Med Chem Lett; 2006 Jan; 16(1):64-8. PubMed ID: 16242322
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Substituted N-aryl-6-pyrimidinones: a new class of potent, selective, and orally active p38 MAP kinase inhibitors.
    Devadas B; Selness SR; Xing L; Madsen HM; Marrufo LD; Shieh H; Messing DM; Yang JZ; Morgan HM; Anderson GD; Webb EG; Zhang J; Devraj RV; Monahan JB
    Bioorg Med Chem Lett; 2011 Jul; 21(13):3856-60. PubMed ID: 21620699
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibitors of unactivated p38 MAP kinase.
    Bullington J; Argentieri D; Averill K; Carter D; Cavender D; Fahmy B; Fan X; Hall D; Heintzelman G; Jackson P; Leung WP; Li X; Ling P; Olini G; Razler T; Reuman M; Rupert K; Russell R; Siekierka J; Wadsworth S; Wolff R; Xiang B; Zhang YM
    Bioorg Med Chem Lett; 2006 Dec; 16(23):6102-6. PubMed ID: 16971122
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Discovery and characterization of triaminotriazine aniline amides as highly selective p38 kinase inhibitors.
    Lin TH; Metzger A; Diller DJ; Desai M; Henderson I; Ahmed G; Kimble EF; Quadros E; Webb ML
    J Pharmacol Exp Ther; 2006 Aug; 318(2):495-502. PubMed ID: 16702443
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 2-(aminoacylamino)benzophenones: farnesyltransferase inhibition and antimalarial activity.
    Kettler K; Wiesner J; Fucik K; Sakowski J; Ortmann R; Dahse HM; Jomaa H; Schlitzer M
    Pharmazie; 2005 Sep; 60(9):677-82. PubMed ID: 16222868
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discovery of PH-797804, a highly selective and potent inhibitor of p38 MAP kinase.
    Selness SR; Devraj RV; Devadas B; Walker JK; Boehm TL; Durley RC; Shieh H; Xing L; Rucker PV; Jerome KD; Benson AG; Marrufo LD; Madsen HM; Hitchcock J; Owen TJ; Christie L; Promo MA; Hickory BS; Alvira E; Naing W; Blevis-Bal R; Messing D; Yang J; Mao MK; Yalamanchili G; Vonder Embse R; Hirsch J; Saabye M; Bonar S; Webb E; Anderson G; Monahan JB
    Bioorg Med Chem Lett; 2011 Jul; 21(13):4066-71. PubMed ID: 21641211
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pyrrolopyridine inhibitors of mitogen-activated protein kinase-activated protein kinase 2 (MK-2).
    Anderson DR; Meyers MJ; Vernier WF; Mahoney MW; Kurumbail RG; Caspers N; Poda GI; Schindler JF; Reitz DB; Mourey RJ
    J Med Chem; 2007 May; 50(11):2647-54. PubMed ID: 17480064
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synthesis, crystal structure, and activity of pyrazole-based inhibitors of p38 kinase.
    Graneto MJ; Kurumbail RG; Vazquez ML; Shieh HS; Pawlitz JL; Williams JM; Stallings WC; Geng L; Naraian AS; Koszyk FJ; Stealey MA; Xu XD; Weier RM; Hanson GJ; Mourey RJ; Compton RP; Mnich SJ; Anderson GD; Monahan JB; Devraj R
    J Med Chem; 2007 Nov; 50(23):5712-9. PubMed ID: 17948975
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pyridinylquinoxalines and pyridinylpyridopyrazines as lead compounds for novel p38 alpha mitogen-activated protein kinase inhibitors.
    Koch P; Jahns H; Schattel V; Goettert M; Laufer S
    J Med Chem; 2010 Feb; 53(3):1128-37. PubMed ID: 20078117
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A novel series of p38 MAP kinase inhibitors for the potential treatment of rheumatoid arthritis.
    Brown DS; Belfield AJ; Brown GR; Campbell D; Foubister A; Masters DJ; Pike KG; Snelson WL; Wells SL
    Bioorg Med Chem Lett; 2004 Nov; 14(21):5383-7. PubMed ID: 15454231
    [TBL] [Abstract][Full Text] [Related]  

  • 20. p38 MAP kinase inhibitors. Part 6: 2-arylpyridazin-3-ones as templates for inhibitor design.
    Natarajan SR; Heller ST; Nam K; Singh SB; Scapin G; Patel S; Thompson JE; Fitzgerald CE; O'Keefe SJ
    Bioorg Med Chem Lett; 2006 Nov; 16(22):5809-13. PubMed ID: 16945533
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.